Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma

Table 4 Select studies on neoadjuvant transarterial radioembolization/selective internal radiation therapy for intrahepatic cholangiocarcinoma

Ref.	Study type	Intervention	Sample size	Conversion to resection	Tumor response
Ibrahim et al[68], 2008	Prospective	Y-90	24	1 (4%)	6PR, 15 SD, 1PD
Mouli et al[69], 2013	Retrospective	Y-90	46	5 (11%)	11 PR, 33 SD, 1 PD
Rayar et al[71], 2015	Retrospective	Gemcitabine followed by Y-90	10	8 (80%)	NR
Saxena et al[72], 2010	Retrospective	Y-90	25	1 (4%)	6 PR, 11 SD, 5 PD
Rafi et al[73], 2012	Prospective	Y-90	19	NR	2 PR, 13 SD, 4 PD
Hoffman et al[74], 2012	Prospective	Y-90	33	NR	12 PR, 17 SD, 5 PD
Riby et al[75], 2020	Retrospective	Y-90	19	19 (100%)	NR
Edeline et al[76], 2019	Phase II Trial	GemCis + Y-90	26	9 (22%)	NR

NR: Not reported; PR: Partial response; SD: Stable disease; PD: Disease progression; ICC: Intrahepatic cholangiocarcinoma.